Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) EBITDA Margin (2017 - 2025)

Arcus Biosciences has reported EBITDA Margin over the past 9 years, most recently at 345.45% for Q4 2025.

  • Quarterly results put EBITDA Margin at 345.45% for Q4 2025, up 5070.0% from a year ago — trailing twelve months through Dec 2025 was 156.28% (down 2837.0% YoY), and the annual figure for FY2025 was 156.28%, down 2837.0%.
  • EBITDA Margin for Q4 2025 was 345.45% at Arcus Biosciences, up from 546.15% in the prior quarter.
  • Over the last five years, EBITDA Margin for RCUS hit a ceiling of 78.45% in Q4 2021 and a floor of 824.66% in Q3 2021.
  • Median EBITDA Margin over the past 5 years was 315.1% (2023), compared with a mean of 357.64%.
  • Peak annual rise in EBITDA Margin hit 178044bps in 2021, while the deepest fall reached -82738bps in 2021.
  • Arcus Biosciences' EBITDA Margin stood at 78.45% in 2021, then tumbled by -377bps to 217.65% in 2022, then tumbled by -199bps to 650.0% in 2023, then soared by 39bps to 396.15% in 2024, then rose by 13bps to 345.45% in 2025.
  • The last three reported values for EBITDA Margin were 345.45% (Q4 2025), 546.15% (Q3 2025), and 5.0% (Q2 2025) per Business Quant data.